GLP-1 Receptor Agonists in Children and Adolescents with Obe
Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...Now open: Certificate Course in Management of Covid-19 by Govt. Of Gujarat and PlexusMDKnow more...
A Study was conducted to determine the weight, BMI, cardiometabolic and gastrointestinal effects of GLP-1 receptor agonists in children with obesity.

GLP-1 receptor agonists' weight, BMI, cardiometabolic, and gastrointestinal effects in children and adolescents with obesity were included in the study. The primary outcomes were weight and cardiometabolic profile, with gastrointestinal-related treatment-emergent adverse effects being a secondary outcome of concern.

Results:
--9 studies involving 574 participants were identified, of which 3 involved exenatide and 6 involved liraglutide.

--GLP-1 receptor agonists use caused a modest reduction in body weight.

--Glycemic control was improved in children with proven insulin resistance (HbA1c MD -1.05).

--Although no lipid profile improvements were noted, a modest decrease in systolic blood pressure was detected (MD -2.30 mmHg).

--Finally, analysis of gastrointestinal-related treatment-emergent adverse events revealed an increased risk of nausea, without significant increases in other gastrointestinal symptoms.

In conclusion, this meta-analysis shows that GLP-1 receptor agonists are safe and effective in clinical settings for reducing weight, BMI, HbA1c, and systolic blood pressure in children and adolescents with obesity, but with increased rates of nausea.

Source: https://www.jpeds.com/article/S0022-3476(21)00432-7/fulltext?rss=yes
Like
Comment
Share